PMID- 21976055
OWN - NLM
STAT- MEDLINE
DCOM- 20160915
LR  - 20160324
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 130
IP  - 3
DP  - 2011 Dec
TI  - Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound 
      paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early 
      stage breast cancer.
PG  - 825-31
LID - 10.1007/s10549-011-1678-9 [doi]
AB  - Every-2-week (dose-dense) adjuvant doxorubicin (A) plus cyclophosphamide (C) 
      followed by cremophor-formulated paclitaxel (cf-P) was efficacious in metastatic 
      breast cancer (BC). Albumin-bound paclitaxel (ab-P) was safe and more effective 
      than cf-P, and the addition of bevacizumab to cf-P improved efficacy. This study 
      compared the safety of dose-dense ab-P vs cf-P plus bevacizumab following 
      dose-dense adjuvant AC for early-stage BC. PATIENTS AND METHODS: Women with 
      operable, histologically confirmed BC were randomized to 4 cycles of dose-dense A 
      60 mg/m(2) plus C 600 mg/m(2) IV with SC pegfilgrastim, followed by 4 cycles of 
      either dose-dense IV ab-P 260 mg/m(2) or cf-P 175 mg/m(2). Bevacizumab was given 
      during and following chemotherapy. 97 and 96% of patients completed 4 cycles of 
      AC therapy, while 84 and 85% of patients completed 4 cycles of taxane therapy in 
      the ab-P and cf-P arms, respectively (N = 197). Baseline patient characteristics 
      were similar. The most common grade >/=3 taxane-related adverse events (AEs) were 
      fatigue and neutropenia. Dose reductions were similar between the treatment arms. 
      During AC therapy, the majority of dose reductions were due to febrile 
      neutropenia; during taxane therapy, the majority of cases were due to neuropathy. 
      No taxane-related dose interruption occurred in the ab-P arm, while 3 occurred in 
      the cf-P arm due to hypersensitivity reactions. The mean cumulative paclitaxel 
      dose was 950.5 and 660.8 mg/m(2) in the ab-P and cf-P arms, respectively. A 44% 
      higher paclitaxel dose was delivered in the ab-P compared with the cf-P arm 
      (P < 0.0001), while achieving a similar safety profile. ab-P plus bevacizumab 
      following AC therapy without prophylactic premedications was tolerable in 
      early-stage BC patients.
FAU - Pippen, John
AU  - Pippen J
AD  - US Oncology Research, 3535 Worth St, Dallas, 75246, TX, USA. 
      john.pippen@usoncology.com.
AD  - Texas Oncology, Dallas, TX, USA. john.pippen@usoncology.com.
AD  - Baylor Sammons Cancer Center, Dallas, TX, USA. john.pippen@usoncology.com.
FAU - Paul, Devchand
AU  - Paul D
AD  - US Oncology Research, Rocky Mountain Cancer Center, Denver, CO, USA.
FAU - Vukelja, Svetislava
AU  - Vukelja S
AD  - US Oncology Research, 3535 Worth St, Dallas, 75246, TX, USA.
FAU - Clawson, Alicia
AU  - Clawson A
AD  - Celgene, Summit, NJ, USA.
FAU - Iglesias, Jose
AU  - Iglesias J
AD  - Celgene, Summit, NJ, USA.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20111006
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Albumin-Bound Paclitaxel)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Albumin-Bound Paclitaxel/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Bevacizumab/administration & dosage
MH  - Breast Neoplasms/*drug therapy/metabolism/*pathology
MH  - Chemotherapy, Adjuvant
MH  - Cyclophosphamide/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - AC therapy
OT  - Albumin-bound paclitaxel
OT  - Bevacizumab
OT  - Dose-dense
OT  - Early stage breast cancer
EDAT- 2011/10/07 06:00
MHDA- 2016/09/16 06:00
CRDT- 2011/10/07 06:00
PHST- 2011/06/28 00:00 [received]
PHST- 2011/07/07 00:00 [accepted]
PHST- 2011/10/07 06:00 [entrez]
PHST- 2011/10/07 06:00 [pubmed]
PHST- 2016/09/16 06:00 [medline]
AID - 10.1007/s10549-011-1678-9 [pii]
AID - 10.1007/s10549-011-1678-9 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2011 Dec;130(3):825-31. doi: 10.1007/s10549-011-1678-9. 
      Epub 2011 Oct 6.